Cell proliferation inhibitors and apoptosis promoters
European Journal of Cancer, Supplement · Published 2020-08-01 · DOI 10.1016/j.ejcsup.2019.09.002
Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2019.09.002
Abstract
Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which cell-cycle alterations are common. P53, a key regulator of checkpoint G1, is frequently altered in high-grade serous ovarian cancer. Targeting cell-cycle regulators will lead to mitotic catastrophe and cell death in these tumours. Promoting apoptosis is another target that is gaining interest in ovarian cancer.In this review, the most relevant evidence of clinical studies in ovarian cancer with compounds targeting cell cycle or promoting apoptosis is summarised.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2020
Related articles
- Urothelial carcinoma management in elderly or unfit patients · European Journal of Cancer, Supplement · 2016 · Same journal
- Inflammation and immunity in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- DNA damaging agents in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- The influence of secreted factors and extracellular vesicles in ovarian cancer metastasis · European Journal of Cancer, Supplement · 2020 · Same journal
- Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study · European Journal of Cancer, Supplement · 2021 · Same journal
- Biosimilars: Extrapolating the evidence. A roundtable discussion · European Journal of Cancer, Supplement · 2015 · Same journal
- Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? · European Journal of Cancer, Supplement · 2021 · Same journal
- Insight updating of the molecular hallmarks in ovarian carcinoma · European Journal of Cancer, Supplement · 2020 · Same journal
- Anti-angiogenic therapy for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- Rare ovarian tumours. Other treatments for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal